Protalix Biotherapeutics Inc. (PLX) Attracts A Huge Investment By A Large Hedge Fund

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
please

specify
the type of institution: _____________________________________

(a)       Amount
beneficially owned:

As of the date hereof, Highbridge Capital
Management, LLC, as the trading manager of Highbridge International LLC and Highbridge Tactical Credit & Convertibles Master
Fund, L.P. (collectively, the “Highbridge Funds“), may be deemed to be the beneficial owner of 6,523,399 shares
of Common Stock held by the Highbridge Funds.

(b)       Percent
of class:

The percentages used herein and in the
rest of this Schedule 13G are calculated based upon 123,777,137 currently outstanding which is the sum of (i) 99,930,402 shares
of Common Stock outstanding as of November 1, 2016, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly
period ended September 30, 2016 filed with the Securities and Exchange Commission on November 9, 2016 and (ii) 23,846,735 shares
of Common Stock issued by the Company in the exchange transaction described in the Current Report on Form 8-K filed by the Company
with the Securities and Exchange Commission on December 7, 2016. Therefore, as of the date hereof, Highbridge Capital Management,
LLC may be deemed to beneficially own approximately 5.3% of the outstanding shares of Common Stock of the Company.

The foregoing should not be construed in
and of itself as an admission by the Reporting Person as to beneficial ownership of the shares of Common Stock held by the Highbridge
Funds.